CSIMarket


Vaxart Inc   (VXRT)
Other Ticker:  
 


 

Vaxart Inc

VXRT's Financial Statements and Analysis



Vaxart Inc narrowed forth quarter of 2023 net loss per share of $-0.10 compare to net loss per share of $-0.18 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.11 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.1 $  3 Mill
$+0.08     $+3M     +14650 %



Vaxart Inc 's Revenue rose by 14650 % in forth quarter of 2023 (Dec 31 2023) year on year, to $3 million and advanced by 54.45 % sequentially.


Vaxart Inc is

More on VXRT's Income Statement



Vaxart Inc 's in theforth quarter of 2023 recorded net loss of $-17.375 million, an improvement compare to net loss of $-23.918 million in IV. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-17.400 million realized in previous quarter.

More on VXRT's Growth

Vaxart Inc Inventories
VXRT's Cash flow In the forth quarter of 2023 company's net cash flow was $2 million


Vaxart Inc does not pay out common stock dividend.

In trailing twelve-month period Vaxart Inc payed $ -0.49 cash per share, on a free-cash flow basis .

Book value fell by -15.07 % sequentially to $0.40 per share, -12.71% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.34 per share from $ 0.41.

Company repurchased 7.35 million shares or 4.84 % in Dec 31 2023.


More on VXRT's Dividends

 Market Capitalization (Millions) 109
 Shares Outstanding (Millions) 145
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Vaxart Inc does not pay out common stock dividend.

In trailing twelve-month period Vaxart Inc had negative $ -0.49 cash flow per share, on a free-cash flow basis .

Book value fell by -15.07 % sequentially to $0.40 per share, -12.71% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.34 per share from $ 0.41.

Company repurchased 7.35 million shares or 4.84 % in Dec 31 2023.


More on VXRT's Balance Sheets

 Market Capitalization (Millions) 109
 Shares Outstanding (Millions) 145
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) -2
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Vaxart Inc Earnings

Vaxart Inc Reports Impressive Financial Results for Q4 2023, Showcasing Strong Growth and Decreased Losses

Vaxart Inc, a biotechnology company based in California, recently announced its financial results for the fourth quarter of 2023, showing significant improvement in various key metrics. The company decreased its loss per share to $-0.10 from $-0.18 in the previous year, while also improving earnings per share from $-0.11 in the prior reporting season. Revenue saw a sharp increase of 14650% to $3.25 million from $0.02 million in the corresponding reporting season a year before, with a sequential increase of 54.45% from $2.10 million.
Additionally, Vaxart reported a net deficit of $-17.375 million for the fourth quarter of 2023, a decrease from the deficit of $-23.918 million in the same period a year ago....

Vaxart Inc Surpasses Expectations with $2.101 Million in Revenue in Recent Fiscal Period

Vaxart Inc: A Promising Sign of Growth and Resilience in the Stock Market
In the world of investments, the stock market has always been an exciting platform for investors to witness companies grow and thrive. Among those promising companies is Vaxart Inc, a leading innovator in the field of biotechnology. With recent financial results that showcase remarkable progress and resilience, Vaxart Inc continues to capture the attention of investors around the globe.
In the most recent fiscal period, Vaxart Inc revealed a remarkable $2.101 million in revenue, a clear indication of the company's ability to generate substantial income. This revenue is a testament to the company's dedication to its mission of d...

Vaxart Inc Registers $1.358M Q2 Revenue Amid Challenging Market Conditions


Vaxart Inc Achieves Astounding 694% Revenue Surge, Unveiling Promising Growth Potential Amid Financial Challenges

Vaxart Inc has reported a staggering 694.118% revenue increase year on year, reaching $0.68 million in the financial time-frame ending on March 31, 2023. However, despite this impressive growth, the company reported a net deficit of $-25.140 million for the same period, larger than the $-25.101 million deficit recorded a year ago.
The company's deficit grew from $-0.18 to $-0.19 per share, while its revenue more than doubled, increasing by 2968.182% from $0.02 million. Despite this financial performance, Vaxart Inc is expected to release its next set of financial results on May 08, 2023.
Despite the net deficit, the significant increase in revenue for Vaxart Inc is surely a positive development for ...


Date modified: 2024-03-15T06:12:28+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com